All News

Top news of the day from across the health care landscape.

Top news of the week from The American Journal of Pharmacy Benefits.

Top news of the week from Specialty Pharmacy Times.

After a hospitalization, age is positively associated with the likelihood of receiving an opioid prescription.

Erenumab-aooe (Aimovig, Amgen) is the first FDA-approved preventive migraine treatment in a new class of drugs that work by blocking the activity of the molecule that is involved in migraine attacks.

Graduating from pharmacy school is a momentous occasion. What's next?

Deprivation in patients with chronic obstructive pulmonary disease (COPD) is associated with increased emergency healthcare use, healthcare costs, and mortality rates, according to research.

Dupilumab (Dupixent) significantly improved disease severity in patients aged 12 to 17 years with moderate-to-severe atopic dermatitis.

Erenumab-aooe (Aimovig, Amgen) is the first FDA-approved preventive migraine treatment in a new class of drugs that work by blocking the activity of the molecule that is involved in migraine attacks.

The FDA approved lofexidine hydrochloride (Lucemyra) for the mitigation of opioid withdrawal symptoms to facilitate abrupt discontinuation of opioids in adults, aged 18 and older.

Community Oncology Alliance survey indicates concern that Medicare Part B reforms will have a negative effect on patient care and drive up costs.

Top news of the day from across the health care landscape.

Data from two phase 3 studies showed that esketamine nasal spray demonstrated improvements in depressive symptoms for patients who did not respond to other antidepressant treatments.

Top news of the day from across the health care landscape.

COPD prevalence is increasing more rapidly in women, particularly in younger women, and COPD-related hospitalizations and deaths in women also surpass men.

A review of authorized and branded generics.

The FDA has approved lofexidine hydrochloride (Lucemyra) for the mitigation of opioid withdrawal symptoms to facilitate abrupt discontinuation of opioids in adults.

While focusing on funding their eventual retirements, pharmacists should also make sure that they are not stuck in unrewarding jobs.

A new rabies test developed at the CDC could mean people exposed to potentially rabid animals would forego the weeks-long regimen of shots to prevent the deadly disease.

Proteus Digital Health announced they have more than 30 drugs in their pipeline with sensors in them. What can pharmacists do to prepare for this?

Eli Lilly’s galcanezumab met its primary endpoint in a phase 3 study evaluating its use in the prevention of episodic cluster headaches.

Prescription medication use for attention-deficit/hyperactivity disorder (ADHD), asthma, and contraception have all increased in children and teens.

Top news of the day from across the health care landscape.

Pharmacy rotations are a great opportunity to get hands on experience before starting your career as a pharmacist.

Top news of the day from across the health care landscape.

The FDA has approved once-daily oral emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (Truvada) in combination with safe sex practices, to reduce the risk of sexually acquired HIV-1 in at-risk adolescents..

The FDA today approved epoetin alfa-epbx (Retacrit) as a biosimilar to epoetin alfa (Epogen/Procrit) for the treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in patients with HIV infection

Designed with exclusive new features for bidirectional electronic medical records integration.

Retacrit gains FDA approval as a biosimilar to Epogen/Procrit for the treatment of anemia caused by chronic kidney disease, chemotherapy, or in patients with HIV.